Department of Obstetrics and Gynaecology, Campus Bio Medico University of Rome, Italy.
Gynecol Oncol. 2012 Nov;127(2):290-6. doi: 10.1016/j.ygyno.2012.07.104. Epub 2012 Jul 20.
To evaluate the efficacy, in terms of safety, overall survival and progression free survival of neoadjuvant chemotherapy followed by radical surgery plus adjuvant chemotherapy in patients affected by locally advanced cervical cancer (stage IB2-IIB) with or without node metastases.
Between June 2000 and February 2007, all patients with diagnosis of locally advanced cervical cancer referred to the Division of Gynecologic Oncology of the University Campus Bio-Medico of Rome were eligible for this protocol. All enrolled patients received 3 cycles of platinum-based chemotherapy every 3 weeks according to the scheme Cisplatin 100mg/mq and Paclitaxel 175 mg/mq. After neoadjuvant chemotherapy all patients with stable or progressive disease were excluded from the protocol, the others were submitted to classical radical hysterectomy, bilateral salpingo-oophorectomy and bilateral systematic pelvic lymphadenectomy and 4 cycles of adjuvant treatment with platinum based chemotherapy were executed.
Concerning intention to treat basis analysis, 5 year overall survival (OS) and disease-free survival (DFS) are 77% and 61%, respectively. The 5-year OS of patients with positive pelvic nodes and those with negative nodes metastases was respectively 60% and 87%. Concerning the according to protocol analysis, the 5-year OS and DFS are 81% and 70% respectively. The 5-year OS in patient with positive and negative lymph nodes is 75% and 88% respectively.
The adjuvant chemotherapy regimen after neoadjuvant chemotherapy and radical surgery represents a valid treatment for patients with locally advanced cervical cancer.
评估新辅助化疗后行根治性手术加辅助化疗治疗局部晚期宫颈癌(IB2-IIB 期)患者的疗效,包括安全性、总生存期和无进展生存期,无论是否有淋巴结转移。
2000 年 6 月至 2007 年 2 月,罗马大学生物医学园区妇科肿瘤学系收治的所有局部晚期宫颈癌患者均符合本方案纳入标准。所有入组患者均接受 3 个周期的铂类为基础的化疗,每 3 周 1 次,方案为顺铂 100mg/mq 和紫杉醇 175mg/mq。新辅助化疗后,所有病情稳定或进展的患者均被排除在方案之外,其余患者接受经典根治性子宫切除术、双侧附件切除术和双侧系统盆腔淋巴结切除术,并进行 4 个周期的铂类辅助治疗。
基于意向治疗基础分析,5 年总生存率(OS)和无病生存率(DFS)分别为 77%和 61%。盆腔淋巴结阳性患者和淋巴结阴性转移患者的 5 年 OS 分别为 60%和 87%。根据方案分析,5 年 OS 和 DFS 分别为 81%和 70%。淋巴结阳性和阴性患者的 5 年 OS 分别为 75%和 88%。
新辅助化疗后行根治性手术加辅助化疗是局部晚期宫颈癌患者的有效治疗方法。